The Opdivo/Yervoy combination has shown incremental toxicity relative to monotherapy in every trial where the combination has been tested, as far as I know. That's why BMY has lowered the doses and/or limited the number of dosing cycles when running these trials.
News 
Market Data 
Discover 
